LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Jiang, Shimin"
  2. AU="Wu, Xue-Ying"
  3. AU="Carlos Augusto de Mattos"
  4. AU="Procopio, Francesco A"
  5. AU="Nagata, Kosei"
  6. AU="Kevin Pottie"
  7. AU=Das Tandrila AU=Das Tandrila
  8. AU="Couto Souza, Paulo Henrique"
  9. AU="Morris, Zachary"

Suchergebnis

Treffer 1 - 10 von insgesamt 68

Suchoptionen

  1. Artikel: Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis.

    Gu, Xia / Jiang, Shimin / Yang, Yue / Li, Wenge

    Diabetology & metabolic syndrome

    2024  Band 16, Heft 1, Seite(n) 14

    Abstract: Objective: To assess the effects of finerenone and glucagon-like peptide 1 receptor agonists (GLP1-RA) on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM), and the relative cardiovascular benefits in patients with or ... ...

    Abstract Objective: To assess the effects of finerenone and glucagon-like peptide 1 receptor agonists (GLP1-RA) on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM), and the relative cardiovascular benefits in patients with or without established atherosclerotic cardiovascular disease for different outcomes with these classes of drugs.
    Methods: We searched PubMed, the Cochrane Library, and Embase from January 1, 2000, to December 30, 2022, to identify randomized controlled trials. The primary outcomes were the composite of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death (MACE); hospitalization for heart failure (HHF); and a composite of renal outcomes. The results were reported as hazard ratios (HRs) with 95% confidence intervals (CIs).
    Results: In total, we identified 11 trials and 73,927 participants, 13,847 (18.7%) in finerenone trials and 60,080 (81.3%) in GLP1-RA trials. Finerenone reduced the risk of MACE by 13% (HR, 0.87; 95% CI, 0.79-0.95; P = 0.003), while GLP1-RA reduced the risk in a similar magnitude by 13% (HR, 0.87; 95% CI, 0.83-0.92; P < 0.001). For both drug classes, the effect on lowering the risk of MACE was restricted to approximately 14% in patients with established atherosclerotic cardiovascular disease (HR, 0.86; 95% CI, 0.82-0.90; P < 0.001), whereas no effect was observed in patients without established atherosclerotic cardiovascular disease (HR, 0.93; 95% CI, 0.85-1.02; P = 0.12). GLP1-RA reduced myocardial infarction, stroke and cardiovascular death more than finerenone (which appeared to have no effect). Only finerenone was beneficial for reducing the risk of HHF (HR, 0.78; 95% CI, 0.66-0.92; P = 0.003). Both finerenone (HR, 0.84; 95% CI, 0.77-0.92; P < 0.001) and GLP1-RA (HR, 0.81; 95% CI, 0.76-0.86; P < 0.001) reduced the risk of kidney disease progression, including macroalbuminuria, and finerenone was superior to GLP1-RA in delaying deterioration of kidney function.
    Conclusions: Finerenone and GLP1-RA lead to a risk reduction in MACE to a similar degree in patients with established atherosclerotic cardiovascular disease. For both drug classes, the effect on lowering the risk of progression of kidney disease was also in a similar magnitude in patients with T2DM, whereas only finerenone had a significant protective effect against HHF. Treatment decisions for patients with T2DM should consider the clinical benefit profiles of each drug.
    Sprache Englisch
    Erscheinungsdatum 2024-01-11
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2518786-7
    ISSN 1758-5996
    ISSN 1758-5996
    DOI 10.1186/s13098-023-01251-2
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Protein restriction for diabetic kidney disease.

    Jiang, Shimin / Fang, Jinying / Li, Wenge

    The Cochrane database of systematic reviews

    2023  Band 1, Seite(n) CD014906

    Abstract: Background: Diabetic kidney disease (DKD) continues to be the leading cause of kidney failure across the world. For decades dietary protein restriction has been proposed for patients with DKD with the aim to retard the progression of chronic kidney ... ...

    Abstract Background: Diabetic kidney disease (DKD) continues to be the leading cause of kidney failure across the world. For decades dietary protein restriction has been proposed for patients with DKD with the aim to retard the progression of chronic kidney disease (CKD) towards kidney failure. However, the relative benefits and harms of dietary protein restriction for slowing the progression of DKD have not been addressed.
    Objectives: To determine the efficacy and safety of low protein diets (LPD) (0.6 to 0.8 g/kg/day) in preventing the progression of CKD towards kidney failure and in reducing the incidence of kidney failure and death (any cause) in adult patients with DKD. Moreover, the effect of LPD on adverse events (e.g. malnutrition, hyperglycaemic events, or health-related quality of life (HRQoL)) and compliance were also evaluated.
    Search methods: We searched the Cochrane Kidney and Transplant Register of Studies up to 17 November 2022 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.
    Selection criteria: We included randomised controlled trials (RCTs) or quasi-RCTs in which adults with DKD not on dialysis were randomised to receive either a LPD (0.6 to 0.8 g/kg/day) or a usual or unrestricted protein diet (UPD) (≥ 1.0 g/kg/day) for at least 12 months.
    Data collection and analysis: Two authors independently selected studies and extracted data. Summary estimates of effect were obtained using a random-effects model. Results were summarised as risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes and mean difference (MD) or standardised MD (SMD) with 95% CI for continuous outcomes. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
    Main results: We identified eight studies involving 486 participants with DKD. The prescribed protein intake in the intervention groups ranged from 0.6 to 0.8 g/kg/day. The prescribed protein intake in the control groups was ≥ 1.0 g/kg/day, or a calculated protein intake ≥ 1.0 g/kg/day if data on prescribed protein intake were not provided. The mean duration of the interventions was two years (ranging from one to five years). Risks of bias in most of the included studies were high or unclear, most notably for allocation concealment, performance and detection bias. All studies were considered to be at high risk for performance bias due to the nature of the interventions. Most studies were not designed to examine death or kidney failure. In low certainty evidence, a LPD may have little or no effect on death (5 studies, 358 participants: RR 0.38, 95% CI 0.10 to 1.44; I² = 0%), and the number of participants who reached kidney failure (4 studies, 287 participants: RR 1.16, 95% CI 0.38 to 3.59; I² = 0%). Compared to a usual or unrestricted protein intake, it remains uncertain whether a LPD slows the decline of glomerular filtration rate over time (7 studies, 367 participants: MD -0.73 mL/min/1.73 m²/year, 95% CI -2.3 to 0.83; I² = 53%; very low certainty evidence). It is also uncertain whether the restriction of dietary protein intake impacts on the annual decline in creatinine clearance (3 studies, 203 participants: MD -2.39 mL/min/year, 95% CI -5.87 to 1.08; I² = 53%). There was only one study reporting 24-hour urinary protein excretion. In very low certainty evidence, a LPD had uncertain effects on the annual change in proteinuria (1 study, 80 participants: MD 0.90 g/24 hours, 95% CI 0.49 to 1.31). There was no evidence of malnutrition in seven studies, while one study noted this condition in the LPD group. Participant compliance with a LPD was unsatisfactory in nearly half of the studies. One study reported LPD had no effect on HRQoL. No studies reported hyperglycaemic events.
    Authors' conclusions: Dietary protein restriction has uncertain effects on changes in kidney function over time. However, it may make little difference to the risk of death and kidney failure. Questions remain about protein intake levels and compliance with protein-restricted diets. There are limited data on HRQoL and adverse effects such as nutritional measures and hyperglycaemic events. Large-scale pragmatic RCTs with sufficient follow-up are required for different stages of CKD.
    Mesh-Begriff(e) Adult ; Humans ; Kidney Failure, Chronic/prevention & control ; Diet, Protein-Restricted/adverse effects ; Diabetic Nephropathies ; Renal Insufficiency, Chronic ; Malnutrition ; Hyperglycemia ; Diabetes Mellitus ; Randomized Controlled Trials as Topic
    Sprache Englisch
    Erscheinungsdatum 2023-01-03
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review ; Research Support, Non-U.S. Gov't ; Systematic Review
    ISSN 1469-493X
    ISSN (online) 1469-493X
    DOI 10.1002/14651858.CD014906.pub2
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  3. Artikel: Correction to: Beraprost Sodium Delays the Decline of Glomerular Filtration Rate in Patients with Diabetic Nephropathy: A Retrospective Study.

    Zhou, Jingjing / Jiang, Shimin / Li, Zhongxin / Li, Wenge

    Diabetes therapy : research, treatment and education of diabetes and related disorders

    2023  Band 14, Heft 3, Seite(n) 507

    Sprache Englisch
    Erscheinungsdatum 2023-02-05
    Erscheinungsland United States
    Dokumenttyp Published Erratum
    ZDB-ID 2566702-6
    ISSN 1869-6961 ; 1869-6953
    ISSN (online) 1869-6961
    ISSN 1869-6953
    DOI 10.1007/s13300-023-01376-7
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel: Beraprost Sodium Delays the Decline of Glomerular Filtration Rate in Patients with Diabetic Nephropathy: A Retrospective Study.

    Zhou, Jingjing / Jiang, Shimin / Li, Zhongxin / Li, Wenge

    Diabetes therapy : research, treatment and education of diabetes and related disorders

    2023  Band 14, Heft 3, Seite(n) 497–506

    Abstract: Introduction: To investigate the reno-protective effect of beraprost sodium (BPS) in patients with diabetic nephropathy (DN).: Methods: We retrospectively analyzed patients with DN hospitalized in China-Japan Friendship Hospital from January 2015 to ... ...

    Abstract Introduction: To investigate the reno-protective effect of beraprost sodium (BPS) in patients with diabetic nephropathy (DN).
    Methods: We retrospectively analyzed patients with DN hospitalized in China-Japan Friendship Hospital from January 2015 to December 2021 who received combination of conventional treatment and BPS (120 ug/day) therapy. We selected patients with DN matched in age and estimated glomerular filtration rate (eGFR) as controls, who received only conventional therapy. Baseline information and clinical variables at each follow-up visit were collected from all patients. The changes of clinical variables were compared between the two groups before and after treatment.
    Results: A total of 50 patients with DN met the inclusion and exclusion criteria, with 25 patients in each group. The baseline characteristics of the two groups have no significant difference (p > 0.05). Serum albumin levels after treatment were improved in both groups, but the improvement was statistically significant only in BPS group (35.5-39.8 g/l, p < 0.001). The eGFR worsened significantly in both groups (p = 0.009 and p = 0.001). However, the decline of eGFR was less in BPS group than that in control group (- 9.8 vs. - 16.7 ml/min/1.73 m
    Conclusions: Combination of conventional treatment and BPS therapy delays the decline of eGFR in patients with DN in the long term.
    Sprache Englisch
    Erscheinungsdatum 2023-01-05
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2566702-6
    ISSN 1869-6961 ; 1869-6953
    ISSN (online) 1869-6961
    ISSN 1869-6953
    DOI 10.1007/s13300-022-01361-6
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Serum PLA2R antibody as a predictive biomarker for venous thromboembolism risk in primary membranous nephropathy.

    Li, Jiayi / Wang, Xu / Jiang, Shimin / Li, Wenge

    Medicina clinica

    2023  Band 161, Heft 10, Seite(n) 417–421

    Abstract: Background: Patients with nephrotic syndrome are at high risk of venous thromboembolism (VTE), especially for primary membranous nephropathy (PMN). The phospholipase A2 receptor (PLA2R) is a marker of primary membranous nephropathy activity. This study ... ...

    Abstract Background: Patients with nephrotic syndrome are at high risk of venous thromboembolism (VTE), especially for primary membranous nephropathy (PMN). The phospholipase A2 receptor (PLA2R) is a marker of primary membranous nephropathy activity. This study investigated the predictive value of PLA2R antibodies in PMN for VTE.
    Methods: In this retrospective study, we included 97 PMN patients and evaluated the predictive value of serum PLA2R antibodies for VTE risk. Lower extremity venous ultrasound, renal vein ultrasound, or spiral computed tomography pulmonary arteriography were used to assess VTE events. Serum anti-PLA2R antibodies were detected by enzyme-linked immunosorbent assay (ELISA). The risk of VTE was stratified according to serum albumin levels.
    Results: Twenty PMN patients (21%) had thromboembolic events. Eight (15%) of patients with serum albumin >25g/l developed VTE, 6 of whom were positive for serum PLA2R antibodies. Positive serum PLA2R antibodies were significantly associated with VTE events in patients with serum albumin >25g/l (p=0.01). Age, sex, blood creatinine, serum albumin, and 24-h urine protein levels were not statistically different between the two groups. Kaplan-Meier analysis using the log-rank test revealed anti-PLA2R positive membranous nephropathy patients had more probability of VTE events than anti-PLA2R negative patients. Univariate Cox proportional hazards analysis revealed that lnPLA2R-Ab is an unfavorable predictor for VTE events in patients with serum albumin >25g/l (hazard ratio (HR) 2.1, p=0.01).
    Conclusions: The PLA2R antibody was a risk predictor for thromboembolic events in patients with primary membranous nephropathy with serum albumin >25g/l.
    Mesh-Begriff(e) Humans ; Glomerulonephritis, Membranous/complications ; Glomerulonephritis, Membranous/diagnosis ; Receptors, Phospholipase A2 ; Venous Thromboembolism/diagnosis ; Venous Thromboembolism/etiology ; Retrospective Studies ; Autoantibodies ; Biomarkers ; Serum Albumin/analysis ; Serum Albumin/metabolism
    Chemische Substanzen Receptors, Phospholipase A2 ; Autoantibodies ; Biomarkers ; Serum Albumin
    Sprache Spanisch
    Erscheinungsdatum 2023-07-31
    Erscheinungsland Spain
    Dokumenttyp Journal Article
    ZDB-ID 411607-0
    ISSN 1578-8989 ; 0025-7753
    ISSN (online) 1578-8989
    ISSN 0025-7753
    DOI 10.1016/j.medcli.2023.06.007
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Ua VI Zs.279: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Innovation efficiency of urban agglomerations in the middle reaches of the Yangtze River based on three-stage DEA model

    JIANG Shimin / WANG Chengyun / XIONG Wenjing

    Journal of Shanghai Normal University (Natural Sciences), Vol 51, Iss 4, Pp 506-

    2022  Band 516

    Abstract: Taking 28 prefecture-level cities in the middle of the Yangtze River as the research object,a three-stage data envelopment analysis(DEA) model was used to measure and analyze the innovation efficiency and its spatial-temporal evolution characteristics in ...

    Abstract Taking 28 prefecture-level cities in the middle of the Yangtze River as the research object,a three-stage data envelopment analysis(DEA) model was used to measure and analyze the innovation efficiency and its spatial-temporal evolution characteristics in the middle reaches of the Yangtze River from 2005 to 2018,and the geographical weighted regression (GWR) model was used to reveal the influencing factors and spatial heterogeneity of the spatial difference of innovation efficiency. The results show that the innovation efficiency of urban agglomerations in the middle reaches of the Yangtze River presents two-stage characteristics,with stable development period from 2005 to 2010 and fluctuating change period from 2011 to 2018. The trend of innovation development of "one circle,two groups" is still unclear,and it is still in the initial stage of innovation development. The spatial variation of innovation efficiency in urban agglomerations in the middle reaches of the Yangtze River from 2005 to 2018 is significant,showing the characteristics of "divergence-convergence-divergence". Economic base (ECO),industrial structure (INDU),foreign investment (FDI),government support (GOV) and urban infrastructure construction (BAS) have significant differences in driving patterns of innovation development in the middle reaches of the Yangtze River agglomerations,with obvious spatial differentiation.
    Schlagwörter urban agglomeration in the middle reaches of the yangtze river ; regional innovation ; innovation efficiency ; data envelopment analysis(dea) model ; Science (General) ; Q1-390
    Thema/Rubrik (Code) 910
    Sprache Englisch
    Erscheinungsdatum 2022-08-01T00:00:00Z
    Verlag Academic Journals Center of Shanghai Normal University
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  7. Artikel ; Online: A bioactive composite hydrogel dressing that promotes healing of both acute and chronic diabetic skin wounds.

    Shang, Shunlai / Zhuang, Kaiting / Chen, Jianwen / Zhang, Ming / Jiang, Shimin / Li, Wenge

    Bioactive materials

    2024  Band 34, Seite(n) 298–310

    Abstract: Mesenchymal stem cell derived exosomes (MSC-Exos) demonstrate beneficial effects on wound healing via anti-inflammatory and angiogenic properties. Chitosan (CS) exhibits excellent biocompatibility and accelerates cellular migration, adhesion, and ... ...

    Abstract Mesenchymal stem cell derived exosomes (MSC-Exos) demonstrate beneficial effects on wound healing via anti-inflammatory and angiogenic properties. Chitosan (CS) exhibits excellent biocompatibility and accelerates cellular migration, adhesion, and proliferation. The ions released from bioactive glass (BG) and titanium dioxide (TiO
    Sprache Englisch
    Erscheinungsdatum 2024-01-03
    Erscheinungsland China
    Dokumenttyp Journal Article
    ISSN 2452-199X
    ISSN (online) 2452-199X
    DOI 10.1016/j.bioactmat.2023.12.026
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  8. Artikel ; Online: Prevalence and prognosis of malignancy in THSD7A-associated membranous nephropathy: a systematic literature review and clinical case study.

    Xu, Qianqian / Li, Jiayi / Yang, Yue / Zhuo, Li / Gao, Hongmei / Jiang, Shimin / Li, Wenge

    Renal failure

    2024  Band 46, Heft 1, Seite(n) 2355353

    Abstract: Background: This study aims to investigate the incidence and prognosis of malignancy in individuals with thrombospondin type-1 domain-containing 7A (THSD7A)-associated membranous nephropathy (MN).: Methods: First, we performed a systematic literature ...

    Abstract Background: This study aims to investigate the incidence and prognosis of malignancy in individuals with thrombospondin type-1 domain-containing 7A (THSD7A)-associated membranous nephropathy (MN).
    Methods: First, we performed a systematic literature review of prevalence of malignancy in THSD7A-associated MN. Then, we conducted a retrospective analysis of 454 patients diagnosed with MN through renal biopsy at our hospital between January 2016 and December 2020. We assessed the presence of serum anti-THSD7A antibodies and performed immunohistochemical staining of renal tissue for THSD7A. Subsequently, we followed patients with THSD7A-associated MN for a minimum of 3-5 years, collecting their clinical, pathological characteristics, and prognosis. Additionally, we conducted a literature review on patients with THSD7A-associated MN in conjunction with malignancy.
    Results: We identified a total of nine articles containing comprehensive data on THSD7A-associated MN and malignancy. Among 235 patients with THSD7A-positive MN, 36 individuals had concurrent malignancies, resulting in a malignancy prevalence of 13.3% (95% CI: 8.9-17.7%). In our center, we followed up with 15 patients diagnosed with THSD7A-associated MN and observed three cases of concomitant tumors: two cases of lung adenocarcinoma and one case of small cell lung cancer with multiple metastases. The prevalence of malignancy in our cohort was 20%. Notably, we detected positive THSD7A staining in both renal and lung cancer tissues in one patient with small cell lung cancer.
    Conclusions: Patients with THSD7A-associated MN should undergo vigilant follow-up assessments, with a particular focus on actively seeking potential tumorigenic lesions to prevent misdiagnosis or oversight.
    Mesh-Begriff(e) Humans ; Glomerulonephritis, Membranous/epidemiology ; Glomerulonephritis, Membranous/pathology ; Glomerulonephritis, Membranous/immunology ; Glomerulonephritis, Membranous/diagnosis ; Prognosis ; Thrombospondins/immunology ; Prevalence ; Retrospective Studies ; Male ; Middle Aged ; Female ; Adult ; Neoplasms/epidemiology ; Aged ; Kidney/pathology
    Chemische Substanzen THSD7A protein, human ; Thrombospondins
    Sprache Englisch
    Erscheinungsdatum 2024-05-24
    Erscheinungsland England
    Dokumenttyp Journal Article ; Systematic Review
    ZDB-ID 632949-4
    ISSN 1525-6049 ; 0886-022X
    ISSN (online) 1525-6049
    ISSN 0886-022X
    DOI 10.1080/0886022X.2024.2355353
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1331: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  9. Artikel ; Online: Worldwide burden and trends of diabetes among people aged 70 years and older, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019.

    Jiang, Shimin / Yu, Tianyu / Di, Dingxin / Wang, Ying / Li, Wenge

    Diabetes/metabolism research and reviews

    2023  Band 40, Heft 3, Seite(n) e3745

    Abstract: Background: Diabetes places a significant burden on personal and public health. However, a comprehensive assessment of the burden of diabetes in older adults is lacking. We aimed to estimate the global burden of diabetes and explore trends for the ... ...

    Abstract Background: Diabetes places a significant burden on personal and public health. However, a comprehensive assessment of the burden of diabetes in older adults is lacking. We aimed to estimate the global burden of diabetes and explore trends for the population aged ≥70 from 1990 to 2019.
    Methods: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, the prevalence, mortality, and disability-adjusted life-years (DALYs) of diabetes among people aged ≥70 were estimated by sex and age group in 2019. We also assessed the epidemiological trend of diabetes from 1990 to 2019.
    Results: In 2019, 110.1 million (95% uncertainty interval [UI]: 101.2-119.4) people aged ≥70 years were living with diabetes (types 1 and 2 combined) with a global prevalence of 23.7% (21.8%-25.8%). Worldwide, 181.9 deaths (163.0-194.7) per 100,000 population and 4512.3 DALYs (3861.3-5264.2) per 100,000 population occurred due to diabetes. In 2019, minor sex-related disparities in the burden of diabetes were identified among specific age and sex groups. From 1990 to 2019, the prevalence of diabetes increased by 39.7% (37.7%-41.7%), and the related mortality and DALY rates also increased (16.4% [9.43%-22.9%] and 22.3% [17.2%-27.0%], respectively).
    Conclusion and relevance: The global burden of diabetes in adults aged ≥70 has increased markedly from 1990 to 2019. As the population continues to age, there is an urgent need to combat the increasing disease burden.
    Mesh-Begriff(e) Humans ; Aged ; Aged, 80 and over ; Global Burden of Disease ; Quality-Adjusted Life Years ; Cost of Illness ; Risk Factors ; Prevalence ; Diabetes Mellitus/epidemiology ; Global Health
    Sprache Englisch
    Erscheinungsdatum 2023-11-09
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1470192-3
    ISSN 1520-7560 ; 1520-7552
    ISSN (online) 1520-7560
    ISSN 1520-7552
    DOI 10.1002/dmrr.3745
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2119: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  10. Artikel ; Online: The Chronic Kidney Disease Epidemiology Collaboration equations perform less well in an older population with type 2 diabetes than their non-diabetic counterparts.

    Jiang, Shimin / Zhang, Danyang / Li, Wenge

    Frontiers in public health

    2022  Band 10, Seite(n) 952899

    Abstract: Objectives: The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations are based on creatinine alone (CKD-EPIcr), cystatin C alone (CKD-EPIcys) and combined creatinine and cystatin C (CKD-EPIcr-cys). It remains unclear whether these ... ...

    Abstract Objectives: The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations are based on creatinine alone (CKD-EPIcr), cystatin C alone (CKD-EPIcys) and combined creatinine and cystatin C (CKD-EPIcr-cys). It remains unclear whether these equations perform differently in older adults with type 2 diabetes than they do in non-diabetic older individuals.
    Methods: This single-center cross-sectional study was performed in adults aged ≥ 65 years between January 2019 and December 2021. Glomerular filtration rate (GFR) was measured by technetium-99m-diethylene triamine pentaacetic acid (
    Results: Finally, 476 participants were enrolled, including 243 adults with type 2 diabetes and 233 non-diabetic adults. The mean age of the included participants was 71.69 ± 6.4 years and 262 (55%) were male. The mean measured GFR was 49.02 ± 22.45 ml/min/1.73 m
    Conclusions: The performance of the CKD-EPI equations was lower in a group of patients aged ≥ 65 years with type 2 diabetes than in non-diabetic counterparts. However, each equation still had limitations regarding accuracy in older adults with or without diabetes.
    Mesh-Begriff(e) Aged ; Creatinine ; Cross-Sectional Studies ; Cystatin C ; Diabetes Mellitus, Type 2 ; Female ; Glomerular Filtration Rate ; Humans ; Male ; Renal Insufficiency, Chronic
    Chemische Substanzen Cystatin C ; Creatinine (AYI8EX34EU)
    Sprache Englisch
    Erscheinungsdatum 2022-08-10
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2711781-9
    ISSN 2296-2565 ; 2296-2565
    ISSN (online) 2296-2565
    ISSN 2296-2565
    DOI 10.3389/fpubh.2022.952899
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang